Study guide

Integumentary, Ostomy, Lymphedema, and Wound Care

OCN Oncology Certified Nurse Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: OCN Exam Orientation and Official Source Control

Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness

2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care

Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures

3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment

Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation

4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards

Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development

5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy

Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation

6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents

Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation

7 Chapter 7: Symptom Management and Supportive Care

Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination

8 Chapter 8: Oncologic Emergencies and Rapid Escalation

Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

9 Chapter 9: Psychosocial Dimensions of Oncology Care

Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals

10 Chapter 10: Mixed OCN Case Labs

New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab

11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness

Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning

Integumentary, Ostomy, Lymphedema, and Wound Care

Key Takeaways Explain This Topic AI

Radiation dermatitis progresses from erythema to dry then moist desquamation; protect the field, avoid friction/adhesives, and never apply metallic or unapproved products before treatment.

Extravasation of a vesicant is an emergency: stop the infusion, leave the catheter to aspirate, do NOT flush, and apply agent-specific antidote and thermal measures (cold for most vesicants, warm for vinca alkaloids).

A healthy stoma is moist and pink-to-red; dusky/black tissue or no output with cramping and distention signals ischemia or obstruction and needs urgent evaluation.

Ileostomies produce high, watery output (often 800-1200 mL/day) creating dehydration and electrolyte risk; barrier opening should clear the stoma by about 1-2 mm.

Lymphedema risk reduction emphasizes skin protection and early reporting; cellulitis (redness, warmth, fever, rapid swelling) is urgent.

Last updated: June 2026

  • Integumentary, Ostomy, Lymphedema, and Wound Care
  • Skin, Wounds, and Radiation Dermatitis

Cancer care injures skin through surgery, radiation, systemic therapy, vascular devices, immobility, edema, malnutrition, and tumor invasion. Assess color, temperature, moisture, turgor, rash pattern, pain, pruritus, open areas, drainage, odor, bleeding, surrounding erythema, and functional impact, and document location, size, and the plan for wound, radiation, surgery, or provider follow-up.

Radiation dermatitis appears in the treatment field and progresses predictably; know the stages for grading questions:

  • Stage / CTCAE grade Appearance Nursing focus
  • Grade 1 Faint erythema, dry desquamation Gentle cleansing, moisturize as approved
  • Grade 2 Brisk erythema, patchy moist desquamation, edema Non-adherent dressings, manage pain
  • Grade 3 Confluent moist desquamation, bleeding with trauma Wound care referral, infection watch
  • Grade 4 Necrosis, full-thickness ulcer Urgent escalation

Teach gentle cleansing, no friction or adhesive trauma in the field, sun protection, and no heating pads, ice, or metallic-based products (some deodorants/zinc) before daily treatment because they can increase the surface dose. Other patterns: hand-foot syndrome (palmar-plantar redness, swelling, peeling from capecitabine, 5-FU, liposomal doxorubicin, and some TKIs), acneiform rash from EGFR inhibitors, and malignant fungating wounds (control odor with metronidazole or charcoal dressings, manage bleeding and dignity).

Vesicant Extravasation: An Emergency

Extravasation of a vesicant (a drug that causes tissue necrosis if it leaks) is an oncologic emergency. The exam-tested sequence: STOP the infusion immediately , disconnect tubing but leave the catheter in place to aspirate residual drug, do NOT flush the line , notify the provider, and apply agent-specific measures. Thermal and antidote choices differ by drug:

Anthracyclines (doxorubicin): cold compress; antidote dexrazoxane ; topical DMSO per policy.

Vinca alkaloids (vincristine, vinblastine): warm compress and hyaluronidase (cold is contraindicated).

Mark and photograph the site per policy, and document drug, volume, site, and interventions.

Ostomy Care and Fluid Risk

A healthy stoma is moist and pink to red ; a dusky, purple, or black stoma signals ischemia and is urgent, as is no output with cramping, vomiting, and distention (obstruction). Teach pouch emptying and changing, measuring the barrier so the opening clears the stoma by about 1-2 mm , peristomal skin protection, odor control, and supply ordering. Ileostomy output is high and watery (often 800-1200 mL/day ), so teach signs of dehydration and electrolyte loss and encourage oral rehydration; output above ~1500 mL/day is a high-output ileostomy needing provider contact.

Urinary diversions require attention to mucus, flow, and infection. Normalize body-image and sexuality concerns and refer to a Wound, Ostomy, and Continence Nurse (WOCN).

Lymphedema

Lymphedema follows lymph-node surgery, radiation, tumor obstruction, or infection and may affect a limb, breast, trunk, or head/neck. Early signs are subtle: rings, sleeves, or watch feeling tight, heaviness, and aching. Risk reduction: meticulous skin care, prompt treatment of cuts, sun and burn protection, gradual activity, and early reporting. Compression garments, manual lymphatic drainage, and complete decongestive therapy are directed by trained clinicians. Cellulitis (redness, warmth, fever, pain, rapid swelling) in an at-risk limb is urgent.

Follow institutional policy on blood pressures and venipuncture in the at-risk limb rather than promising they always cause lymphedema. Reassess all skin and appliance care: is pain improving, is drainage increasing, can the patient perform care, are supplies available, and is swelling responding to the plan?

Targeted-Therapy Skin Toxicities

Modern regimens bring distinct dermatologic patterns that OCN candidates must recognize. Epidermal growth factor receptor (EGFR) inhibitors (cetuximab, erlotinib, panitumumab) commonly cause an acneiform (papulopustular) rash on the face and trunk, paronychia, and dry, fissured skin; interestingly, rash severity often correlates with treatment response, so the goal is to manage it, not to stop therapy reflexively. Teaching includes gentle skin care, broad-spectrum sunscreen, and using prescribed topical or oral antibiotics rather than over-the-counter acne products, which dry the skin further.

Multikinase inhibitors (sorafenib, sunitinib) cause a hand-foot skin reaction with painful, hyperkeratotic, callus-like areas at pressure points, managed with cushioning, urea-based creams, and pressure offloading. The nurse distinguishes these from chemotherapy hand-foot syndrome and from cellulitis, because the management and escalation triggers differ.

Body Image, Self-Care, and Reassessment

Skin, wound, ostomy, and lymphedema changes carry heavy psychosocial weight, and ignoring that weight undermines adherence. A new ostomy, a fungating wound with odor, hair and nail changes, or a swollen limb can isolate a patient and erode self-esteem and sexual confidence. The nurse normalizes these reactions, invites questions without judgment, includes the caregiver when the patient agrees, and connects the patient to support resources and the WOCN.

Practical self-care assessment matters as much as wound staging: can the patient see the stoma, manage the barrier with their hand dexterity, afford and obtain supplies, and reach help after hours? Reassessment then verifies real outcomes, not just intentions, confirming that the dermatitis is healing, the stoma output and skin are stable, the limb measurements are improving with therapy, and the patient can actually perform the care taught. Visible findings always get tied back to the treatment history so the team can act on the underlying driver.

The nurse also documents objectively, using consistent measurements, wound descriptors, and photographs only where policy permits, so that change over time, healing, worsening, or a new infection, is unmistakable to every clinician who follows.